Сумма биотехнологии. Руководство по борьбе с мифами о генетической модификации растений, животных и людей

441. Ravikumar B. et al.: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature genetics 2004, 36(6):585–95.

442. Beauchamp E.M., Platanias L.C.: The evolution of the TOR pathway and its role in cancer. Oncogene 2013, 32(34):3923–32.

443. Saiki S. et al.: Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy 2011, 7(2):176–87.

444. Zhou H. et al.: Updates of mTOR inhibitors. Anti-cancer agents in medicinal chemistry 2010, 10(7):571–81.

445. Dowling R.J. et al.: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007, 67(22):10804–12.

446. Chin R.M. et al.: The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature 2014.

447. Leontieva O.V. et al.: Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging cell 2014.

448. Fok W.C. et al.: Mice fed rapamycin have an increase in life span associated with major changes in the liver transcriptome. PLOS ONE 2014, 9(1):e83988.

449. Miller R.A. et al.: Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 2014, 13(3):468–77.

450. Harrison D.E. et al.: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460(7253):392–5.

451. Baur J.A. et al.: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337–42.

452. Miller R.A. et al.: Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. The journals of gerontology Series A, Biological sciences and medical sciences 2011, 66(2):191–201.

453. Elmadhun N.Y. et al.: Alcohol Consumption Mitigates Apoptosis and Mammalian Target of Rapamycin Signaling in Myocardium. Journal of the American College of Surgeons 2014.

454. Foster D.A.: Reduced mortality and moderate alcohol consumption: the phospholipase D-mTOR connection. Cell cycle 2010, 9(7):1291–4.

455. Yu X. et al.: Beneficial and harmful effects of alcohol exposure on Caenorhabditis elegans worms. Biochemical and biophysical research communications 2011, 412(4):757–62.

456. Correia S. et al.: Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem 2008, 8(13):1343–54.

457. Onken B., Driscoll M.: Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLOS ONE 2010, 5(1):e8758.

458. Martin-Montalvo A. et al.: Metformin improves healthspan and lifespan in mice. Nat Commun 2013, 4:2192.

459. Chin R.M. et al.: The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature 2014, 510(7505):397–401.

460. Bhattacharya R. et al.: Toxicity of alpha-ketoglutarate following 14-days repeated oral administration in Wistar rats. Cellular and molecular biology 2011, 57 Suppl: OL1543–9.

461. Bhattacharya R., Vijayaraghavan R.: Promising role of alpha-ketoglutarate in protecting against the lethal effects of cyanide. Human & experimental toxicology 2002, 21(6):297–303.

462. Bhattacharya R. et al.: Biochemical, oxidative and histological changes caused by sub-acute oral exposure of some synthetic cyanogens in rats: Ameliorative effect of alpha-ketoglutarate. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 2014, 67:201–11.

463. Hariharakrishnan J. et al.: Cyanide-induced changes in the levels of neurotransmitters in discrete brain regions of rats and their response to oral treatment with alpha-ketoglutarate. Indian journal of experimental biology 2010, 48(7):731–6.

464. Bienholz A. et al.: Adverse effects of alpha-ketoglutarate/ malate in a rat model of acute kidney injury. American journal of physiology Renal physiology 2012, 303(1):F56–63.

465. Coudray-Lucas C. et al.: Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls. Critical care medicine 2000, 28(6):1772–6.

466. Donati L. et al.: Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients. Clinical nutrition 1999, 18(5):307–11.

467. De Bandt J.P. et al.: A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients. The Journal of nutrition 1998, 128(3):563–9.

468. Campbell B. et al.: Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult men. Nutrition 2006, 22(9):872–81.